Personalized Synthetic Long Peptide Vaccine (NCI)

The Personalized Synthetic Long Peptide Vaccine is an investigational, neoantigen-based immunotherapy developed by the National Cancer Institute (NCI) for the treatment of metastatic triple-negative breast cancer (TNBC). This personalized biologic consists of synthetic long peptides (SLPs) that are custom-designed for each patient based on unique somatic mutations identified through genomic sequencing of their tumor. The vaccine is administered subcutaneously alongside the adjuvant poly-ICLC (a TLR3 agonist) to stimulate the production of neoantigen-specific T cells. In clinical settings, such as the Phase 2 trial NCT03606967, it is evaluated in combination with chemotherapy (nab-paclitaxel) and dual checkpoint inhibition (durvalumab and tremelimumab) to overcome tumor-induced immunosuppression and enhance clinical efficacy.

Other names

Neoantigen VaccinePersonalized SLP VaccineSLP Neoantigen VaccinePersonalized Synthetic Long Peptide Vaccine